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appears possible that in the presence of a high molar excess of misfolded protein, such as might occur 
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Extracellular Chaperones and Amyloids 
 
Mark R Wilson, Justin J Yerbury, and Stephen Poon 
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ABSTRACT 
The pathology of more than 40 human degenerative diseases is associated with 
fibrillar proteinaceous deposits called amyloid. Collectively referred to as protein 
deposition diseases, many of these affect the brain and the central nervous system. In 
many cases the amyloid deposits are extracellular and are found associated with 
newly identified abundant extracellular chaperones (ECs). Evidence is discussed 
which suggests an important regulatory role for ECs in amyloid formation and 
disposal in vivo. This is emerging as an exciting field. A model is presented in which 
it is proposed that, under normal conditions, ECs stabilize extracellular misfolded 
proteins by binding to them, and then guide them to specific receptors for uptake and 
subsequent degradation. In this scenario, EC receptors are a critical part of a quality 
control system which protects the brain against dangerously hydrophobic 
proteins/peptides. However, it also appears possible that in the presence of a high 
molar excess of misfolded protein, such as might occur during disease, the limited 
amounts of ECs available may actually exacebate pathology. Further advances in 
understanding of the mechanisms that control extracellular protein folding are likely 
to identify new strategies for effective disease therapies.  
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1.0 INTRODUCTION 
The term "molecular chaperone" was first developed in the late 1970's when referring 
to the ability of nucleoplasmin to inhibit inappropriate interactions between histones 
and DNA (Laskey et al., 1978). The meaning of this term is continuing to evolve but 
two key properties of molecular chaperones are (i) selective binding to non-native 
protein conformations to form stable complexes, and (ii) inhibition of the irreversible 
aggregation of non-native protein conformations (Fink 1999). Many molecular 
chaperones maintain other proteins in "folding-competent" conformations, which are 
returned to the native conformation by the involvement of other refolding chaperones. 
Previous studies have overwhelmingly focussed on intracellular molecular chaperones 
and their roles in protein folding within the cell. The discoveries that a range of 
serious human diseases are related to protein aggregation phenomena, and that 
molecular chaperones affect these processes, has led to a recent explosion of research 
in this area. The pathology of more than 40 human degenerative diseases is associated 
with the deposition of fibrillar proteinaceous aggregates called amyloid. Collectively 
referred to as protein deposition diseases, these include various sporadic (e.g. 
Alzheimer’s (AD) and Parkinson’s (PD) diseases), familial, and transmissible 
degenerative disorders (e.g. spongiform encephalopathies such as Creutzfeldt-Jakob 
disease (CJD)), many of which affect, amongst other tissues and organs, the brain and 
the central nervous system (CNS). In many cases, molecular chaperones have been 
found physically associated with amyloid deposits, although the reason for this 
association remains to be established.  
 
It is notable that many neurodegenerative disorders are associated with extracellular 
amyloid deposits. It has only recently become apparent that extracellular counterparts 
to the intracellular molecular chaperones exist. These proteins share functional 
characteristics with the small heat shock proteins in that they are able to efficiently 
stabilize misfolded proteins to prevent them aggregating but are not capable of 
independently refolding such proteins. Strikingly, in all cases tested, at least one or 
more of these "extracellular chaperones" (ECs) are associated with amyloid deposits 
found outside cells (Table 1). The role of these abundant ECs in the formation of 
amyloid deposits in vivo is emerging as an exciting field. In this chapter, we first 
briefly discuss what is understood about the molecular basis of amyloid formation 
before examining the available evidence that ECs influence this process and 
discussing the potential roles of ECs in amyloid formation and disposal in vivo. 
 
2.0 AMYLOIDS AND THE BRAIN  
 
2.1 Amyloid formation  
The hallmark of a wide range of debilitating and incurable human pathologies is the 
abnormal presence of extracellular deposits in a variety of organs and tissues, 
including the brain and CNS (e.g. AD, CJD), peripheral organs such as the heart, liver, 
and spleen (e.g. systemic amyloidoses), and skeletal tissues and joints (e.g. 
haemodialysis-related amyloidosis). The extent of in vivo deposition can vary 
significantly depending on the disease state as well as the location of the deposits. For 
instance, deposits associated with neurodegenerative diseases of the brain typically 
weigh as little as a few grams whilst systemic deposits can accumulate to quantities of 
as much as several kilograms (Pepys 1995).  
Amyloid fibrils arise when a specific protein or protein fragment converts from an 
otherwise soluble form into insoluble filamentous aggregates. Key fibril-forming 
proteins associated with amyloid deposits and diseases have included full-length 
globular proteins, bioactive peptides (e.g. calcitonin), and fragments of whole proteins 
produced by specific cellular processing (e.g. the processing of amyloid precursor 
protein (APP) to yield Aβ) or by natural degradation. In recent years, it has become 
apparent that the self-assembly of proteins into amyloid fibrils is not restricted to the 
relatively small number of proteins associated with the protein deposition diseases. 
An increasing body of evidence points to this phenomenon as being a generic 
property of polypeptide chains, suggesting that most, if not all, proteins have the 
potential to form amyloid fibrils if exposed to appropriate conditions (Dobson 1999). 
What triggers the in vivo conversion of a protein from its native state into amyloid 
fibrils is not known, however, several important determinants of the fibrillation of 
proteins have been identified, including hydrophobicity and net charge (Chiti and 
Dobson 2006). At present, a detailed understanding of the mechanism for the 
transition from soluble precursors to mature amyloid fibrils is lacking. Despite this, it 
seems that the aggregation behaviours of various amyloid-forming peptides and 
proteins are strikingly similar. Often described as a hierarchical process involving 
multiple stages of assembly, the kinetics of amyloid formation (as measured by ThT 
fluorescence or light scattering) is generally characterized by an initial ‘lag’ or 
nucleation phase, followed by a rapid exponential ‘growth’ or polymerization phase 
(Jarrett and Lansbury 1993), and lastly, by a plateau phase in which no further 
polymerization occurs (Fig. (1)). 
 
The lag (or nucleation) phase is defined as the time required for the formation of the 
soluble (prefibrillar) oligomers or nuclei. This phase begins with the destabilization 
and partial unfolding of the native protein, leading to the formation of an ensemble of 
intermediately folded species. In vitro studies show that structural perturbation 
leading to protein unfolding can be achieved by exposing the native protein to one or 
more chaotropic conditions, including elevated temperature, low pH, oxidative stress, 
molecular crowding, and protease-mediated degradation (Kelly 1998). In vivo, the 
fate of the proteins within the ensemble of partially unfolded intermediates depends 
on the environmental conditions present at the time of their existence. Some proteins 
may be re-folded, whilst others may be degraded. A subset of proteins within this 
ensemble will undergo non-ordered aggregation to form nuclei. When viewed by 
transmission electron (TEM) or atomic-force (AFM) microscopy, these species may 
appear as small beads that are linked together to produce what are often described as 
amorphous aggregates or micelles (Yong et al., 2002). The nucleation phase, which 
constitutes the rate-limiting step in amyloid formation, is relatively slow, due largely 
to unfavourable protein association equilibria rather than to intrinsically slow 
association rates (Jarrett and Lansbury 1993). After nucleation and immediately 
preceding the polymerization phase, the nuclei transform into an ensemble of various 
assemblies called protofibrils that exhibit increased levels of complexity and order. 
During the polymerization phase, these protofibrils rapidly grow via the addition of 
either monomers or oligomers that are formed after the initiation of the aggregation 
process, leading to the formation of well-ordered protofilaments. The lateral 
association of such protofilaments, accompanied by minor structural reorganization, is 
thought to give rise to the formation of mature amyloid fibrils (van Gestel and de 
Leeuw 2007). 
 
Regardless of their individual protein composition, the molecular architecture of all 
amyloid fibrils shares some striking similarities. Despite a lack of information 
detailing the structure of amyloid fibrils at the atomic level, techniques such as X-ray 
fibre diffraction, solid-state NMR, and cryoelectron microscopy have given insights 
into how proteins pack together to form such highly ordered structures. Typically, 
amyloid fibrils exist as long, unbranched, but often twisted structures that are 6-12 
nanometres in diameter, bearing a characteristic ‘cross-β’ X-ray fibre diffraction 
pattern (Sunde and Blake 1997). Each fibril is usually comprised, within its core 
structure, of two to six ‘protofilaments’ that wind around each other to form 
supercoiled rope-like structures. Protofilaments are believed to be principally 
stabilized by intra- and intermolecular interactions (e.g. hydrogen bonds) and are 
composed of β-sheets whose strands lie perpendicular to the long axis of the fibril 
(Serpell 2000; Serpell et al., 2000).  
 
2.2 Amyloid pathology in the brain 
Protein deposition diseases are typically characterized by protein aggregates in 
specific regions of the brain, neuronal death and brain function decline. In the case of 
AD, pathological symptoms include both large anatomical and microscopic changes, 
and are generally characterized by gross diffuse atrophy, primarily in the frontal, 
temporal and parietal regions of the cortex, and extensive neuronal loss. Microscopic 
features, commonly detected by histological staining procedures, include extracellular 
amyloid plaques and intracellular neurofibrillary tangles (Gorevic et al., 1986). 
Pathological features of PD, on the other hand, include the accumulation of Lewy 
bodies within the cytoplasm of pigmented neurons of the cerebral cortex. Yet, for 
CJD, no obvious gross pathology, besides neuronal loss and gliosis, is ever observed 
due to the short course of the lethal disease. Despite advances in understanding of the 
pathological basis of the various amyloid-related neuropathies, the actual cause/s of 
disease remains undetermined and are the subject of intense investigation. Numerous 
theories have been advanced to account for the pathology of amyloid diseases. Many 
of these theories particularly focus on the toxic nature of amyloids and how this 
relates to neuronal loss in the brain (reviewed in (Stefani and Dobson 2003)). 
 
One theory proposes that disease pathology might simply be attributed to the shear 
bulk of deposited material present in the affected organs and tissues, such as the brain. 
It suggests that the extensive accumulation of amyloid deposits causes physical 
disruption to the cellular architecture, subsequently leading to organ dysfunction. 
Another theory suggests that the formation of pores or channels in neuronal cells by 
oligomeric species formed from the self-association of partially unfolded proteins 
may be a critical determinant of amyloid-related neuropathy. Consistent with this idea, 
atomic force microscopy (AFM) has shown that Aβ, the primary constituent of senile 
plaques, can form pore-like structures in vitro (Chromy et al., 2003; Lashuel et al., 
2003). In addition, ion flux data indicate that synthetic Aβ can form cation-selective 
channels across model membranes, leading to increased membrane permeability, 
disruption of calcium homeostasis and associated cellular degeneration (Arispe et al., 
1993). Similar pore forming activity has also been reported for amylin, the major 
component of type-II diabetes-associated islet β-amyloid (Mirzabekov et al., 1996) 
and Cu/Zn superoxide dismutase (SOD1), which is associated with amyotrophic 
lateral sclerosis (ALS) (Chung et al., 2003). 
 
A more recent and widely accepted theory proposes that soluble, inherently toxic 
species are the primary cause of pathogenesis in disorders such as AD. Until recently, 
neuronal cell death was attributed to the presence of mature fibrils, the most common 
form of proteinaceous aggregates present in pathological deposits. Yet, an increasing 
quantity of data suggests that the highly toxic species are in fact the pre-fibrillar 
structures (e.g. oligomers and protofibrils), rather than the mature fibrils into which 
they develop. Exemplifying this, small, soluble and diffusible Aβ oligomers (often 
refered to as amyloid β-derived diffusible ligands or ADDLs) have been shown to be 
highly toxic to cultured neuronal cells, even at nanomolar concentrations (Dahlgren et 
al., 2002). The demonstration that these species are, in addition to being highly 
cytotoxic, readily diffusible throughout the brain may explain why neuronal loss is 
commonly observed at sites distant from those of the amyloid deposits. By proposing 
that the primary toxic species are the early aggregates, this theory also provides a 
plausible explanation for the lack of correlation between the extent of deposition of 
mature fibrils in the form of amyloid plaques in the diseased brain and the severity of 
clinical symptoms (Katzman et al., 1988).   
 
Protein aggregation is often accompanied by the production of reactive oxygen 
species (ROS), although the reason/s for this is not entirely understood. There is 
evidence to indicate that oxidative stress, arising from the ageing process or from the 
production of ROS, contributes to disease pathology. The observation that Aβ 
deposition in the brain is positively correlated with regions of oxidative stress and 
neurodegeneration supports this notion (Hensley et al., 1995). Lending further support 
is the demonstration that antioxidants such as lipoic acid and resveratrol can protect 
cells against aggregate-mediated toxicity (Savaskan et al., 2003; Jesudason et al., 
2005). Disease pathology is believed to arise because oxidative stress reduces the 
expression levels and activity of the multicatalytic proteosome (MCP), which is 
normally responsible for ubiquitin ATP-dependent degradation of aberrant protein 
structures. The reduction of available MCP leads to the accumulation of oxidized and 
damaged proteins at levels that are sufficient to induce neuronal cell death (Keller et 
al., 2000). 
 
2.3 Potential control mechanisms? 
Inside cells the collective functions of chaperones, the ubiquitin-proteasome system 
and lysosome-mediated autophagy is usually sufficient to prevent accumulation of 
misfolded proteins. However, under certain conditions the capacity of this quality 
control system is exceeded and protein aggregates accumulate (Muchowski and 
Wacker 2005). Intracellular levels of molecular chaperones in the brain are thought to 
be lowered with increasing age (Hay et al., 2004), which may contribute to the often 
late onset of protein deposition diseases. Overexpression of intracellular heat shock 
proteins (HSPs) in the nematode Caenorhabditis elegans promotes longevity, and in 
the same system a reduction in the level of heat shock factors (transcriptional 
activators) and thus HSPs shortens lifespan (Westerheide and Morimoto 2005). These 
results suggest that intracellular chaperones are vital in the continuous fight against 
misfolded protein aggregation and amyloid formation. As a corollary, it appears likely 
that in diseases involving extracellular protein deposition, the extracellular processes 
that normally operate to inhibit protein aggregation and to clear protein deposits may 
be impaired - they are certainly overwhelmed. This is supported by the observation 
that, apart from people carrying mutations that result in increased production of Aβ 
(e.g. presenilins or APP genes), the rate of formation of Aβ does not increase with age 
(Deane et al., 2004) but its normally efficient removal from the cerebrospinal fluid 
(CSF) is slowed in aged humans (Zlokovic et al., 2000).  
 
Understanding of the mechanisms controlling protein folding in extracellular spaces, 
especially in the CNS, is in its infancy. However, there is evidence to suggest that 
there are such mechanisms. For example, although CSF is regularly released into the 
venous system through the arachnoid villi, the half lives of proteins in the CSF differ 
from protein to protein, and even differ between various proteolytic fragments of the 
same original protein (Savage et al., 1998), suggesting a selective mechanism of 
removal. Recently it was proposed that there is an extracellular protein quality control 
system consisting of abundant secreted ECs that recognise and facilitate the disposal 
of non-native or dangerously hydrophobic proteins via receptor-mediated cell uptake 
(Yerbury et al., 2005). These proteins may patrol the CNS for misfolded proteins and 
under normal conditions prevent their aggregation and mediate their clearance. 
 
3.0 EXTRACELLULAR CHAPERONES 
 
In the extracellular environment, protein concentrations may be high, as in human 
plasma (about 70 mg/ml), or lower such as in human CSF (120-640 µg/ml) (Williams 
and Marshall 2001). Exposure to stresses capable of inducing protein unfolding is 
common (e.g. sheer stress in extracellular fluids, hyperthermia, oxidative stress, 
transient pH fluctuations), and ATP is 1000 times less abundant than inside cells 
(Farias et al., 2005). In the event of a large-scale presentation of extracellular non-
native protein(s), such as might occur during amyloid disease, only ATP-independent, 
physically abundant extracellular chaperone(s) could reasonably be expected to 
provide an effective line of defense. Intracellular chaperones (e.g. Hsp70, Hsp90) are 
present in human plasma and CSF and are associated with cell surfaces (in particular 
cancer cells); they are thought to be released from dead or dying cells. Many 
potentially important extracellular roles have been proposed for these chaperones, 
such as cancer cell invasiveness (Eustace et al., 2004), immune presentation (Becker 
et al., 2002) and signaling (Whittall et al., 2006). However, these “normally 
intracellular” chaperones are present extracellularly at very low (ng/ml) levels and 
require ATP to carry out protein refolding. Thus, the capacity of the low levels of 
Hsp70 and similar chaperones present extracellularly would be quickly exceeded. 
Therefore, it is far more likely that bulk processing of non-native proteins is dealt 
with by much more abundant proteins with chaperone properties, herafter referred to 
as extracellular chaperones (ECs), which have only recently been identified. 
 
Four secreted glycoproteins, clusterin (Humphreys et al., 1999), haptoglobin (Yerbury 
et al., 2005), α2-macroglobulin (French et al., 2007) and serum amyloid P component 
(SAP) (Coker et al., 2000), have been shown to exhibit chaperone properties in vitro. 
These four proteins share some notable similarities. All four are secreted 
glycoproteins widely distributed in most physiological fluids, including plasma and 
CSF (Barrett 1981; Baltz et al., 1982; Bowman and Kurosky 1982; Humphreys et al., 
1999). Moreover, all bind to a broad range of ligands (Barrett 1981; Capiau et al., 
1986; Katnik et al., 1987; Aruga et al., 1993; Katnik et al., 1993; Zahedi 1996; 
Ashton et al., 1997; Langlois et al., 1997; Zahedi 1997; Kurdowska et al., 2000; 
Wilson and Easterbrook-Smith 2000; Kimura et al., 2001; Sen and Heegaard 2002) 
and have been found associated with clinical amyloid deposits in vivo (Table (1)) 
(Powers et al., 1981; Baltz et al., 1982; Van Gool et al., 1993; McHattie and Edington 
1999; Calero et al., 2000). In addition all have been shown to mediate receptor-
mediated endocytosis of ligands (see below). In terms of the chaperone action, 
clusterin is currently the best characterized. 
 
3.1 Clusterin 
Clusterin is a protein secreted from many different cell types that is found in human 
plasma, CSF and seminal fluid at concentrations of approximately 100, 2, and 1000 
µg/ml (Fritz et al., 1983; Murphy et al., 1988; Choi-Miura et al., 1992), respectively. 
It can also transit from the cell secretory system to the cytosol during certain stress 
conditions, although the reasons why this occurs remain to be established (Nizard et 
al., 2007). Clusterin mRNA is nearly ubiquitous in animal tissues, being found in 
locales as diverse as the rat prostate gland and quail neuroretinal cells. The expression 
of clusterin is increased in a wide variety of models of stress and disease, including 
withdrawal of growth factors and exposure to noxious agents (Jenne and Tschopp 
1992). The clusterin promoter contains a highly conserved 14 bp element which is 
recognized by the transcriptional regulator heat shock factor 1 (HSF1) (Michel et al., 
1997). HSF1 activates expression of heat shock proteins (which protect cells from 
stresses) and clusterin (Michel et al., 1997). Across different mammalian species, the 
amino acid sequence of the protein is maintained at the level of 70-80% (Jenne and 
Tschopp 1992). Clusterin is encoded by a single gene and the translated product is 
internally cleaved to produce its α and β subunits prior to secretion from the cell. 
Matrix-assisted laser desorption ionization mass spectrometry has identified two 
primary forms of human plasma clusterin at about 58 kDa and 63.5 kDa, which 
probably represent different glycoforms. The exclusively N-linked glycosylation is 
variable in nature and extent, ranging from 17-27% (by weight) (Kapron et al., 1997). 
The function of the glycosylation is unknown, although it may be involved in 
recognition by cell surface receptors (Stewart et al., 2007). Probably because of the 
substantive and variable glycosylation, when analysed by SDS PAGE, clusterin 
migrates as a broad band corresponding in position to a mass of 70-80 kDa. In 
aqueous solution at physiological pH, clusterin exists in a range of oligomeric forms; 
mildly acidic pH favours partial dissociation of oligomers into individual α-β 
heterodimers (Hochgrebe et al., 2000). Current insights into clusterin structure are 
largely reliant upon predictions based on sequence analyses, which suggest that the 
protein has significant contiguous regions of disordered (possibly molten globule) 
conformation that separate other regions of well-defined secondary structure, such as 
amphipathic α-helical regions and coiled-coil α-helices (Dunker et al., 2001; Dunker 
et al., 2002). On this basis, clusterin has been categorized as an intrinsically 
disordered protein (Dunker et al., 2001; Dunker et al., 2002). The high level of 
disorder, variable glycosylation and tendency to form oligomers have so far limited 
attempts to structurally characterise clusterin by approaches such as NMR, X-ray 
crystallography and mass spectrometry.  
 
Recent studies have demonstrated that clusterin has chaperone activity with a potent 
ability to influence the amorphous and fibrillar aggregation of many different proteins. 
Clusterin potently inhibits stress-induced protein aggregation by ATP-independent 
binding to exposed regions of hydrophobicity on non-native proteins to form soluble, 
high molecular weight complexes (Humphreys et al., 1999; Poon et al., 2000; 
Yerbury et al., 2007). Immunoaffinity depletion of clusterin from human plasma 
renders proteins in this fluid more susceptible to aggregation and precipitation (Poon 
et al., 2002). Clusterin lacks the ability to independently refold heat-stressed, non-
native enzymes but, like the small heat shock proteins, is able to preserve heat-
inactivated enzymes in a state competent for subsequent ATP-dependent refolding by 
Hsc70 (Poon et al., 2000). However, because there is no currently known abundant 
refolding-competent EC, the physiological significance of this remains uncertain. 
During amorphous aggregation of proteins, clusterin appears to interact with slowly 
aggregating species on the off-folding pathway. 
 
By complexing with misfolded extracellular proteins, ECs like clusterin may mediate 
their cellular uptake and degradation (Yerbury et al., 2005). Clusterin has long been 
known to interact with the cell surface receptor megalin (LRP2) and to complex with 
Aβ to mediate its uptake by megalin and subsequent degradation (Hammad et al., 
1997). It also interacts with other members of the low density lipoprotein (LDL) 
receptor family - it binds to chicken LR8 and an LDLR-related protein (Mahon et al., 
1999), and uptake of clusterin-leptin complexes by apoER2 and VLDLR  has been 
proposed to facilitate leptin clearance (Bajari et al., 2003). Furthermore, clusterin and 
LRP1/megalin have been implicated in the clearance of cellular debris by non-
professional phagocytes (Bartl et al., 2001).  
 
3.2 Haptoglobin 
Haptoglobin (Hp) is a secreted acidic glycoprotein (20% of its total mass is N-linked 
carbohydrate (Bowman and Kurosky 1982)) produced mainly in the liver and found 
in most body fluids of humans and other mammals. Normally, it is present in human 
plasma at 300-2000 µg/ml (Bowman and Kurosky 1982) and CSF at 0.5-2 µg/ml 
(Sobek and Adam 2003). However, the levels of Hp in human plasma are increased 
up to 8-fold during inflammation, various infections, trauma, tissue damage and in 
association with neoplasia, leading to it being designated as an "acute phase protein" 
(Bowman and Kurosky 1982; Dobryszycka 1997). Hp is encoded by a single gene; 
uniquely, in humans, there are two principal alleles (Hp1 and Hp2), which results in 
individual humans expressing one of three major Hp phenotypes (Hp 1-1, Hp 2-1, Hp 
2-2). In all cases, Hp can be represented as a multimer of an αβ subunit. In its 
simplest form (Hp 1-1), Hp consists of a disulfide-linked (α1)2β2 structure (~100 kDa). 
However, in Hp 2-1 and Hp 2-2, an additional cysteine residue in the α2 chain allows 
the formation of a complex series of various sized disulfide-linked αβ polymers (~100 
to ~500 kDa).  
 
Hp binds with extremely high affinity to hemoglobin (Hb) (KD ~ 10-15 M; (Bowman 
and Kurosky 1982)). Formation of the Hp-Hb complex inhibits Hb-mediated 
generation of  lipid peroxides and hydroxyl radical, which is thought to occur in areas 
of inflammation (Dobryszycka 1997). Although it was previously thought that Hp 
cleared the body of vascular Hb released from damaged red blood cells, recent work 
has shown that the ablation of Hp expression in mice had no significant effect on Hb 
clearance following experimentally induced severe hemolysis. Nevertheless, the Hp 
knock-out mice suffered substantially greater mortality under these conditions, which 
was attributed to greater oxidative stress (Lim et al., 1998).  Therefore, it appears 
likely that Hp exerts an important anti-inflammatory action in vivo by inhibiting 
oxidative damage mediated by free Hb (Lim 2001). A variety of other putative 
functions have also been ascribed to Hp. It has been implicated in immune regulation 
(Louagie et al., 1993), shown to inhibit cathepsin B activity (Snellman and Sylven 
1967) and to have pro-angiogenic effects (Cid et al., 1993). Binding of Hp to human 
neutrophils has been reported to inhibit respiratory burst activity (Oh et al., 1990). In 
addition, neutrophils have been shown to take up exogenous Hp and store it within 
cytoplasmic granules - they subsequently secrete it into the local extracellular 
environment in response to a variety of pro-inflammatory stimuli (e.g. yeast, TNFα, 
or the chemotactic peptide fMLP (Wagner et al., 1996; Berkova et al., 1999)). Thus, 
the available evidence indicates that Hp is likely to play an important role in 
suppressing inflammatory responses.  
 
Human Hp specifically inhibits the precipitation of a wide variety of proteins induced 
by a range of stresses (Pavlicek and Ettrich 1999; Yerbury et al., 2005). All three 
human Hp phenotypes exert this chaperone action, although at equivalent mass 
concentrations, at least for one substrate protein tested, Hp1-1 was the most efficient. 
Like clusterin, Hp forms stable, soluble high molecular weight complexes with 
misfolded proteins. Also like clusterin, Hp lacks ATPase activity and has no 
independent ability to refold misfolded proteins. The possibility that Hp holds 
misfolded proteins in a state competent for refolding by other chaperones is currently 
untested. Immunoaffinity depletion of Hp from human serum significantly increased 
the amount of protein that precipitated in response to stresses (Yerbury et al., 2005). 
Thus, Hp has the ability to protect many different proteins from stress-induced 
amorphous precipitation and its effects in whole human serum suggest that this 
activity is likely to be relevant in vivo. Currently, there are no published studies of the 
effects of Hp on amyloid formation, although Hp is found associated with amyloid 
deposits in vivo (Table (1)). 
 
When complexed to Hb, Hp is known to bind to the CD163 cell surface receptor 
(Graversen et al., 2002). Other receptors to which Hp alone binds are the 
CD11b/CD18 integrin (Mac-1/CR3), which also binds denatured proteins and the 
iC3b fragment of complement (Ross 2000), and the CD22 B lymphocyte receptor. 
Unidentified specific Hp binding sites have also been reported to occur on neutrophils 
(Oh et al., 1990) and mast cells (El-Ghmati et al., 2002). Thus, it appears feasible that 
Hp might interact with one or more of these receptors to mediate the clearance and 
degradation of misfolded extracellular proteins. 
 
 
3.3  α2-Macroglobulin (α2M) 
α2-Macroglobulin (α2M) is a major human blood glycoprotein, comprised of ~10% 
carbohydrate by mass. It is assembled from four identical 180 kDa subunits into a 720 
kDa tetramer; the 180 kDa subunits are disulphide bonded to form dimers, which non-
covalently interact to yield the final tetrameric quaternary structure (Jensen and 
Sottrup-Jensen 1986). α2M is present in human plasma and CSF at 1500-2000 
(Sottrup-Jensen 1989) and 1-3.6 µg/ml (Biringer et al., 2006), respectively. It has a 
well known ability to inhibit a broad spectrum of proteases, which it accomplishes 
using a unique trapping method. When exposed to a protease, α2M undergoes limited 
proteolysis at its bait region leading to a large conformational change, physically 
trapping the protease within a steric “cage” (Sottrup-Jensen 1989). The trapped 
protease forms a covalent linkage with α2M by reacting with an intramolecular thiol 
ester bond to yield a conformationally altered form known as “activated” or “fast” 
α2M (α2M*), which exposes a receptor recognition site for low density lipoprotein 
receptor related protein (LRP) (Sottrup-Jensen 1989). By directly interacting with the 
thiol ester bond, small nucleophiles such as methylamine can also activate α2M 
(Imber and Pizzo 1981).  
 
Aside from its interactions with proteases, α2M binds to Aβ peptide and β2-
microglobulin, which are associated with Alzheimer’s disease (Narita et al., 1997)  
and dialysis related amyloidosis (Motomiya et al., 2003), respectively, to cytokines 
and growth factors (Mettenburg et al., 2002), and to a range of hydrophobic 
molecules including endotoxin, phenyl-Sepharose, and liposomes (Barrett 1981). The 
binding to hydrophobic molecules does not inhibit the trapping of proteases and is not 
known to be associated with any conformational changes (Barrett 1981). Previous 
work has indicated that α2M-polypeptide complexes are immunogenic (Chu and 
Pizzo 1993; Binder et al., 2001). α2M bound peptides are internalised by LRP and 
fragments of the peptide are subsequently re-presented on the cell surface. This 
response is identical to the one elicited by peptides chaperoned by intracellular heat 
shock proteins (Srivastava 2002). A further hint that α2M might have chaperone 
properties came from the observation that it inhibits the aggregation of Aβ and 
protects cells from Aβ toxicity (Du et al., 1997). It was recently shown that α2M has a 
promiscuous ATP-independent chaperone action similar to that of both clusterin and 
haptoglobin. It forms stable complexes with misfolded proteins to inhibit their stress-
induced aggregation and precipitation but is unable to independently effect their 
refolding (French et al., 2007). α2M is the first known mammalian protein with both 
protease inhibitor and chaperone-like activities. 
 
Selective removal of α2M from whole human serum renders proteins in this fluid 
more susceptible to precipitation, even at 37 oC (French et al., 2007), suggesting that 
the in vitro chaperone properties of α2M are likely to be relevant in vivo. The effects 
of clusterin, haptoglobin and α2M on plasma protein precipitation are additive 
(French et al., (2007) and unpublished data), suggesting that even though they are 
promiscuous in their interactions with different substrate proteins, the ECs may provide 
complementarity with respect to the endogenous extracellular proteins they protect. 
Interaction with a misfolded substrate protein does not activate α2M and the resulting 
complex is not bound by LRP. However, if the complex subsequently interacts with 
and traps a protease, then the activated conformation is adopted and the 
α2M/protease/misfolded protein complex is bound by LRP (French et al., 2007). Thus, 
for example, interaction with abundant proteases at sites of inflammation may be one 
in vivo switch to trigger LRP-mediated uptake of α2M/misfolded protein complexes. 
Although LRP is the only known receptor for α2M, it remains possible that non-
activated α2M/misfolded protein complexes are taken up via other currently unknown 
cell surface receptors. Like the other ECs, it has been proposed that α2M patrols 
extracellular spaces for misfolded proteins and facilitates their disposal via receptor 
mediated cellular uptake. This activity would contribute to important anti-
inflammatory actions of α2M in vivo. 
 
 
3.4 Serum amyloid P component 
SAP is a member of the pentraxin family of proteins which are characterised by five 
identical subunits noncovalently associated to form a disc-like structure. The SAP 
pentamer consists of five 25 kDa subunits each containing 204 amino acids and a 
single intra-chain disulfide bond, and constructed from multiple anti-parallel β-strands 
arranged in two sheets (Emsley et al., 1994). Each human SAP subunit bears an 
invariant N-linked biantennary oligosaccharide which constitutes more than 8% of the 
mass of the molecule (Pepys et al., 1994).  It has been proposed that SAP circulates as 
a decamer with two pentameric discs noncovalently bound face to face (Wood et al., 
1988; Emsley et al., 1994). Other reports claim that SAP exists as a single pentamer 
in the body and that the decameric form is obtained only upon purification (Sorensen 
et al., 1995; Aquilina and Robinson 2003). SAP is synthesised and catabolized in the 
liver, and is present in human plasma and CSF at concentrations of ~ 40 µg/mL 
(Hutchinson et al., 1994) and 8.5 µg/ml (Hawkins et al., 1994), respectively. Whereas 
SAP is an acute-phase protein in mice (Pepys et al., 1979), in humans it's plasma 
concentration is not significantly elevated during acute inflammation (Pepys et al., 
1978). 
 
Each subunit monomer has two Ca2+-binding sites and shows Ca2+-dependent binding 
to many different ligands, including certain oligosaccharides, glycosaminoglycans 
(Hamazaki 1987), fibronectin (de Beer et al., 1981), C-reactive protein (Swanson et 
al., 1992), aggregated IgG (Brown and Anderson 1993),  C1q (Sorensen et al., 1996),  
complement C4-binding protein (Sorensen et al., 1996), DNA (Pepys and Butler 
1987), chromatin (Breathnach et al., 1989), histones (Hicks et al., 1992), and 
phosphoethanolamine-containing compounds such as phosphatidylethanolamine 
(Emsley et al., 1994). Interaction with these ligands localises SAP to elastic 
microfibrils (Breathnach et al., 1981), glomerular and alveolar basement membrane, 
arterioles, bronchioles, sarcolemma of cardiac and smooth muscle (Dyck et al., 1980), 
and all forms of amyloid (Pepys et al., 1979).  
 
Previous studies of the chaperone properties of SAP are insufficient in number and 
depth to allow unequivocal classification of SAP, together with clusterin, haptoglobin 
and α2M as a genuine EC. However, one study showed that when added to a refolding 
buffer containing denatured lactate dehydrogenase (LDH), SAP markedly enhanced 
the yield of active LDH. The reaction was supra-stoichometric, as a ratio of SAP 
pentamer to LDH substrate of 10:1 was needed to recover 25% of enzyme reactivity 
(Coker et al., 2000). This suggests that SAP is an inefficient refolding-competent 
chaperone. It is important to note that this in vitro activity was demonstrated in the 
absence of ATP and any "helper" chaperones. Clearly, further studies of the 
chaperone properties of SAP and how they might relate to known ECs will be 
valuable. Of particular interest in the current context, SAP has been found present in 
all amyloid deposits examined (Breathnach et al., 1981; Coria et al., 1988; Kalaria et 
al., 1991; Yang et al., 1992). The interaction between SAP and amyloid fibrils is 
highly specific, and the abundance of SAP in amyloid fibrils relative to its trace 
concentration in plasma is extraordinary (Botto et al., 1997). SAP has a protease-
resistant β-pleated sheet structure that in the presence of Ca2+ is resistant to 
proteolysis (Kinoshita et al., 1992). Furthermore, it has been shown that SAP inhibits 
the degradation of several types of amyloid fibrils by proteases. Tennent et al. (1995) 
suggested that SAP protects amyloid from proteolytic degradation in vivo by binding 
to fibrils and masking fibrillar conformation.  
 
4.0 THE EFFECTS OF EXTRACELLULAR CHAPERONES ON AMYLOID 
FORMATION AND TOXICITY 
 
4.1 Effects of ECs on amyloid formation in vitro 
In vivo amyloid formation and deposition is, in terms of its nature, onset, and 
progression, an extraordinarily complex process that can occur over much of the 
lifetime of an individual, thus making it difficult to monitor and study over a 
reasonable timescale.  The co-deposition of other components, including proteins (e.g. 
molecular chaperones), metals, and glycosaminoglycans, adds further complexity to 
the situation. Such complexity prevents the amyloid-forming process from being fully 
reproduced in a test tube. Nevertheless, by examining indvidual steps in the process in 
vitro, it is still possible to gain insight into many facets of in vivo amyloid formation 
and deposition. In vitro, conditions can be manipulated such that fibril formation can 
be assessed in a manageable timeframe. Perturbation of the environment, with the 
specific aim of increasing the population of aggregation-prone intermediates, is a 
common strategy that usually involves, but is not limited to, the use of polypeptide 
concentrations that exceed physiological levels, alterations to pH or ionic strength, the 
use of denaturants, or incubation at high temperatures. Much of the current 
knowledge regarding the effects of ECs on amyloid formation has been gleaned from 
in vitro studies that utilise such strategies. 
 
The in vitro chaperone actions of clusterin, haptoglobin, α2M, and SAP, have been 
previously reported (see section 3.0). Whilst many studies have highlighted the ability 
of these EC to suppress amorphous aggregation, their effects on amyloid formation 
are, apart from clusterin, less well-documented. A report published in 1994 provided 
the first indication that clusterin is capable of preventing amyloid fibril formation 
(Oda et al., 1994). In this report, it was shown that the formation of Aβ fibrils could 
be inhibited by sub-stoichiometric levels of clusterin, a finding which has since been 
confirmed by other independent studies (Matsubara et al., 1996; Hughes et al., 1998). 
Since then, clusterin has been shown to potently inhibit, in a dose-dependent manner, 
the formation of fibrils derived from a broad range of other unrelated ‘substrates’, 
including prion protein Pr106-126 (McHattie and Edington 1999), Apo C-II (Hatters et 
al., 2002), chicken egg white lysozyme, calcitonin, κ-casein, α-synuclein, β2-
microglobulin, PI3-SH3, Aβ, a model peptide CCβw (Yerbury et al., 2007), and the 
naturally occurring amyloidogenic variant of lysozyme, I56T (Kumita et al., 2007). 
Similar inhibitory capabilities have also been documented for α2M. Like clusterin, 
sub-stoichiometric levels of α2M (at a 1:8 molar ratio of α2M:substrate) were enough 
to completely inhibit the formation of fibrillar Aβ aggregates (Hughes et al., 1998). 
Finally, it was shown that in vitro a 1:5 molar ratio of SAP to target protein 
completely attenuated the fibrillation of Aβ1-42 and α1-antitrypsin-derived C-terminal 
peptides (Janciauskiene et al., 1995). There are no published data to show whether 
haptoglobin has similar anti-amyloidogenic properties in vitro. 
 
The ability of sub-stoichiometric levels of clusterin, α2M, or SAP to inhibit 
fibrillogenesis suggests that the substrate species involved is not highly populated but 
is crucial for fibril formation. Studies probing the mechanisms of clusterin's 
chaperone action have provided some indications as to the identity of such species. 
Recent studies exploring the interactions between clusterin and amyloid forming 
proteins revealed that clusterin did not bind to the native form of the substrates tested, 
nor did it interact with mature fibrils (Kumita et al., 2007; Yerbury et al., 2007). 
Interestingly, the greatest amount of anti-amyloidogenic effect afforded by clusterin 
was detected when it was present during the early stages of fibrillogenesis. Yet, based 
on results obtained by mass spectrometry, the presence of clusterin did not eliminate 
the appearance of a partially unfolded monomeric intermediate identified as the initial 
step in the pathway of lysozyme amyloidosis (Kumita et al., 2007). The addition of 
clusterin during the elongation phase did not greatly alter the kinetics of aggregation 
of I56T lysozyme (Kumita et al., 2007). Similarly, clusterin was more effective at 
suppressing fibril formation in solutions of Aβ and SH3 which had been seeded with 
samples taken from corresponding aggregation mixtures during the lag phase 
compared with those taken from the late (plateau) phase (Yerbury et al., 2007). This 
is consistent with data showing that at the same molar clusterin:substrate ratio, as the 
concentration of amyloid forming protein is increased, clusterin is less able to inhibit 
the formation of amyloid by Apo C-II, PI3-SH3 and Aβ. The increased concentration 
of amyloid forming protein increases the abundance of destabilised monomer, 
favouring self-association into oligomers able to nucleate the aggregation process and 
thereby shortening the lag phase (Hatters et al., 2002; Yerbury et al., 2007).  
 
Taken together, the above results suggest that clusterin primarily exerts its effects on 
amyloid formation at or near the nucleation stage. It is likely to be a destabilized pre-
fibrillar oligomeric species that are targets for binding by clusterin.  During amyloid 
formation, conformationally rearranged proteins and oligomeric species are usually 
present at concentrations low enough to account for the potent sub-stoichiometric 
effects of the ECs; when in equilibrium with the native fold, destabilised and non-
native structures can initiate aggregation when present at an abundance as low as 1% 
(Canet et al., 2002; Marcon et al., 2005). The binding of ECs such as clusterin and 
α2M probably reduces the availability of these species to participate in the nucleation 
events that normally precedes fibril formation (Fig. (2)). 
 
The broad-range specificity of clusterin for amyloid forming substrates is not only 
impressive but suggests that the effects of clusterin on amyloid formation may be 
generic. This suggests that there may be a structural feature common amongst 
amyloid-forming peptides and proteins that are specifically recognised by the 
chaperone. Whether this is also true for other ECs is not known. Nevertheless, under 
experimental conditions that favour the formation of amorphous aggregates, both 
clusterin and α2M have been shown to form high molecular weight complexes with 
denatured proteins, at least in part, through hydrophobic interactions (section 3.1 and 
French et al., (2007)).  
 
Given that hydrophobicity is considered to be an important universal determinant in 
the formation of fibrillar protein aggregates (Chiti et al., 2002), it is therefore feasible 
that the inhibitory effects of clusterin, α2M, and SAP on in vitro amyloid formation 
can be attributed to similar hydrophobic interactions between the chaperones and their 
amyloidogenic substrates. In support of this notion, clusterin and α2M (activated and 
non activated) seem to preferentially bind intermediate protein species formed during 
amyloid-related aggregation but do not bind to native structures of the same proteins 
(Narita et al., 1997; Lauer et al., 2001; Hatters et al., 2002; Mettenburg et al., 2002; 
Kumita et al., 2007; Yerbury et al., 2007). Five times more clusterin-Aβ complex was 
formed when clusterin was incubated for 18 h at 37oC with Aβ monomer than was the 
case when it was incubated under the same conditions with pre-aggregated Aβ 
(Matsubara et al., 1995). Similarly, α2M did not initially form complexes with Aβ but 
under conditions that promote amyloid formation stable α2M-Aβ complexes were 
formed after 2 hours (Narita et al., 1997). This pattern of binding may be explained 
by the different levels of hydrophobicity exposed on the various protein 
conformations produced at different stages of the amyloid-forming pathway. For 
example, the level of exposed hydrophobicity on a native protein is generally low 
with hydrophobic residues buried inside the molecule. However, after the protein has 
been destabilized some of the originally buried hydrophobic residues will become 
accessible to the solvent and perhaps chaperones. Subsequent protein aggregation will 
again bury most of the hydrophobic residues inside the aggregating structure. 
 
The relationship between α2M and Aβ is complex due to its two functional 
conformations. There is no doubt that α2M binds to Aβ with high affinity. However, 
there are conflicting reports of the particular α2M conformations that bind to Aβ. 
There are several reports claiming that Aβ binds to active α2M but not to native α2M 
(Narita et al., 1997; Lauer et al., 2001; Mettenburg et al., 2002). In contrast, others 
claim that native α2M binds to Aβ (Du et al., 1997; Hughes et al., 1998). Moreover, 
native α2M can inhibit fibril formation (Du et al., 1997; Hughes et al., 1998), 
providing additional evidence that α2M in its native state can bind Aβ. The binding of 
Aβ occurs in a site that is distinct from the protease and growth factor binding sites 
(Mettenburg et al., 2002). It is most probable that the binding occurs to a linear 
sequence of amino acids, as both activated and native α2M bind Aβ after they have 
been denatured (Mettenburg et al., 2002). In a curious combination of functions, 
activated α2M seems to be able to feed Aβ inside its “cage” to facilitate its proteolysis 
by a trapped protease (Qiu et al., 1996; Lauer et al., 2001). 
 
Despite many reports of the ability of ECs to inhibit fibril formation in vitro, there are 
indications to suggest that they may, at least under certain conditions, actually 
promote the formation or maintain the persistence of amyloid fibrils. α2M binds to 
and protects prion protein from degradation by proteinase K; this protection was not 
exerted by α2M binding to and inhibiting proteinase K (Adler and Kryukov 2007). In 
addition, another study showed that α2M prevents the trypsin-mediated degradation of 
fibrils composed of either immunoglobulin lambda (λ) light chains or β2M (Gouin-
Charnet et al., 1997). Similarly, the calcium-dependent binding of SAP to amyloid 
fibrils formed from Aβ, serum amyloid A protein or immunoglobulin light chain, 
protected the fibrils from subsequent protease-mediated degradation (Tennent et al., 
1995). This in turn led to suggestions that SAP may promote the persistence of 
amyloid deposits in vivo.  
 
For some protein substrates, at low clusterin:substrate ratios (1:50-1:500), clusterin 
promotes the formation of aggregates with an increased level of thioflavin T 
fluorescence, suggesting that (at these ratios) it promoted the formation of fibrils from 
calcitonin, α-synuclein and Aβ. At these low levels, clusterin was found incorporated 
into insoluble Aβ and SH3 fibrils (Yerbury et al., 2007). Similarly, at low SAP:Aβ 
ratios, SAP promoted the formation of Aβ aggregates (Hamazaki 1995); at SAP:Aβ 
of 1:1000, short fibrillar-like structures lacking typical amyloid features were formed 
which often contained associated SAP molecules (Janciauskiene et al., 1995). In 
addition, α2M has been shown to stabilize a conformation of the prion protein 
resistant to proteinase K (PrPRes) that is thought to initiate aggregation and is 
associated with prion disease pathology (Adler and Kryukov 2007). Taken together, 
these results suggest that when ECs are present at low levels relative to the substrate 
they may act to stabilize an otherwise unstable conformation and facilitate amyloid 
fibril formation (Fig. (3)). 
 
4.2 The in vitro effects of ECs on amyloid toxicity 
Recent studies have indicated that the location of amyloid deposits in vivo do not 
correlate well with sites of neurotoxicity (e.g. in AD (Kirkitadze et al., 2002), ALS 
(Lee et al., 2002), Parkinson’s disease (Volles and Lansbury 2003) and familial 
amyloidotic polyneuropathy (Sousa et al., 2001)). Neuronal losses associated with 
these disorders may be brought about by toxicity exerted by smaller soluble 
aggregates (sometimes referred to as oligomers or protofibrils; see section 2.2) (Chiti 
and Dobson 2006). These protofibrils have been shown to be more toxic than both the 
protein/peptide from which they are made and mature fibrils constructed from them 
(Bucciantini et al., 2002). If this scenario is correct, then it follows that at least under 
some conditions EC-mediated inhibition of protein aggregation in the brain could 
actually promote neurotoxicity. When tested against neuronal cell lines, under certain 
specific conditions, clusterin and α2M were shown to promote the neurotoxicity of 
Aβ (clusterin - PC12 cells (Oda et al., 1995); α2M - LAN5 cells (Fabrizi et al., 2001)). 
In stark contrast, using primary rat mixed neuronal cultures, others have demonstrated 
that clusterin and α2M can protect cells from Aβ toxicity (Boggs et al., 1996; Du et 
al., 1997). Even within individual studies, depending on the conditions used, clusterin 
was shown both to protect cells and to promote cytotoxicity. Complexes of clusterin 
and Aβ formed at high ratios of clusterin:Aβ (e.g. 1:10) were less toxic to SH-SY5Y 
cells than Aβ alone; in contrast, complexes formed at low ratios of clusterin:Aβ (e.g. 
1:500) were more toxic than Aβ alone (Yerbury et al., 2007). Thus, the effects of ECs, 
and in particular clusterin, on the toxicity of aggregates are complex and have been 
shown to depend upon the clusterin:substrate ratio, the stage of amyloid formation at 
which the aggregates are formed, and the cell type. 
 
It has been postulated that the level of hydrophobicity exposed by aggregates may 
determine their toxicity (Chiti and Dobson 2006). How this directly relates to the 
mechanism of their toxicity is uncertain and is currently a hotly researched topic, but 
it is probably due to interactions of hydrophobic residues with membranes or other 
molecules essential for normal cellular function (Chiti and Dobson 2006). This, in 
part, may explain the differential effects of clusterin on toxicity.  When the substrate 
protein is present at a high molar excess, clusterin may be unable to mask all regions 
of exposed hydrophobicity but instead may stabilize aggregates which retain 
sufficient exposed hydrophobicity to exert toxicity (Fig. (3)). In contrast, at higher but 
still sub-stoichiometric ratios of clusterin:Aβ, toxicity is reduced (Yerbury et al., 
2007).  
 
Another potentially important factor to consider when trying to understand the in vivo 
effects of ECs on amyloid toxicity, is that in addition to their effects on the nature and 
size of protein aggregates, ECs may also be involved in the physical clearance of 
protein aggregates. This is illustrated by the demonstration that in the presence of 
α2M (but not otherwise), SH-SY5Y cells expressing the α2M receptor (LRP) are more 
resistant to Aβ toxicity than cells that do not (Fabrizi et al., 2001). The protective 
effect of α2M could be inhibited by RAP (a pan-specific inhibitor of LRP ligand 
binding). Furthermore, α2M promoted Aβ toxicity against LRP-negative LAN5 cells 
but had the opposite effect with LRP-expressing LAN5 transfectants (Fabrizi et al., 
2001). Therefore, although ECs may provide cells with some protection by binding to 
exposed hydrophobic regions on protein aggregates, a further protective mechanism 
may only come into play when appropriate cell surface receptors are available to 
mediate uptake and degradation of EC-substrate protein complexes.  
 
4.3 ECs and protein disposal in the brain 
It has been proposed that ECs are scavengers for hydrophobic proteins in the 
extracellular space, inhibiting protein aggregation and deposition and guiding 
misfolded proteins to specific receptors for their internalization and subsequent 
lysosomal degradation ((Yerbury et al., 2005) and see Fig. (3)). This system of EC 
directed receptor-mediated endocytosis may play a major role in the maintenance of 
protein solubility in the extracellular fluids in the brain (interstitial fluid and CSF). 
Evidence supporting this model includes: 
(1) In the CNS, ECs are produced locally in astrocytes and some neuron populations 
(Lauro et al., 1992; Zwain et al., 1994; Klimaschewski et al., 2001) and can be 
transported from plasma across the blood brain barrier (BBB) (Zlokovic 1996). The 
receptors LRP and megalin are expressed on the surface of cells in contact with CSF 
(i.e. chloroid plexus and ependymal cells (Kounnas et al., 1994) and at the BBB 
(Zlokovic 1996; Donahue et al., 2006) and LRP is also found on the surface of 
astrocytes (Arelin et al., 2002) and microglial cells (Laporte et al., 2004).  
(2) Clusterin and α2M are both found complexed with soluble amyloid-forming 
proteins in human CSF (Ghiso et al., 1993; Adler and Kryukov 2007).  
(3) It has previously been shown that clusterin-Aβ complexes bind to megalin on the 
surface of mouse teratocarcinoma F9 cells, and are subsequently internalised, 
transported to lysosomes and degraded (Hammad et al., 1997). Similarly, α2M-Aβ 
complexes are internalized via LRP expressed on U87 cells and are subsequently 
degraded (Narita et al., 1997).  
(4) The normally rapid removal of radiolabelled Aβ from mouse brain is significantly 
inhibited by the LDL family inhibitor RAP and antibodies against LRP-1 and α2M 
(Shibata et al., 2000). Furthermore, when complexed with clusterin, the rate of 
clearance of Aβ1−42 from the mouse brain across the BBB into plasma is increased by 
more than 80% and this transport is significantly inhibited by anti-megalin antibodies 
(Bell et al., 2007).  
 
4.4 When quality control is compromised? 
If a system of extracellular protein quality control (QC) operates and is efficient, why 
do protein deposits sometimes develop? Protein aggregation in the brain is generally 
age-related, and some proteins such as Aβ accumulate as a part of normal aging 
(Fukumoto et al., 1996). In young, healthy humans the disposal of proteins such as 
transthyretin or peptides like Aβ is efficient (that is there are no apparent protein 
deposits). Thus, it is likely that protein deposition may represent an age-dependent 
overloading of the QC system that ultimately results in toxicity and 
neurodegeneration. If the QC system is overloaded in amyloid diseases of the brain, it 
is critical to pinpoint the factors and pathways involved to facilitate identification of 
new potential therapeutic strategies.  
 
One poorly understood pathway relates to the observation that under some conditions 
ECs can actually promote the formation of amyloid fibrils; clusterin, α2M and SAP 
have been shown to promote fibril formation in vitro (Hamazaki 1995; Adler and 
Kryukov 2007; Yerbury et al., 2007) (see section 4.1). In addition, in a transgenic 
mouse model expressing APP (PDAPP mice), a comparison of clusterin -/- and 
clusterin +/+ mice showed no difference in the amount of Aβ deposited in the brain, 
however the amount of thioflavin S positive material was larger in clusterin +/+ mice 
(DeMattos et al., 2002). Although there was no electron microscopy data to confirm 
that this was in fact amyloid fibrils, the authors suggest that this demonstrates 
clusterin promoted fibril formation in this model. In contrast, PDAPP apoE−/−, 
clusterin−/− mice had significantly increased Aβ levels in CSF and intersititial fluid 
and thioflavin–S  deposits in the brain (DeMattos et al., 2004). The results of this 
latter study were interpreted as suggesting that clusterin works cooperatively with 
ApoE to inhibit the formation of Aβ amyloid in the brain. The interpretations 
presented from these two studies are seemingly contradictory, and a clear 
understanding of the in vivo role of clusterin in amyloidogenesis has yet to be 
achieved. An important factor influencing the nature of the effect of clusterin on 
amyloid formation, at least in vitro, is the clusterin:substrate protein ratio. At very low 
ratios of clusterin:substrate, clusterin has been shown to enhance amyloid associated 
thioflavin T fluorescence suggesting that it increases amyloid formation, while at 
higher but still sub-stoichiometric ratios have the opposite effect (see section 4.1). A 
similar biphasic effect on amyloid formation has also been shown for the intracellular 
yeast chaperone hsp104 (Shorter and Lindquist 2004).  
 
It is possible that at times in local microenvironments of the CNS, the concentrations 
of ECs are low and that under these conditions they actually promote the formation of 
amyloid fibrils. Interestingly, under conditions of high substrate protein excess, 
clusterin becomes incorporated into insoluble aggregates (Yerbury et al., 2007). 
Sequestration of clusterin into deposits would effectively lower it's availability, and 
potentially further promote fibril formation. If the other ECs behave similarly, then it 
is no surprise that all are found associated with plaques (see Table (1), and Fig. (3)). 
In humans with AD (Duguid et al., 1989; May et al., 1989) and Creutzfeldt Jacob 
disease (Duguid et al., 1989; Sasaki et al., 2002) the levels of clusterin mRNA are 
increased, however, there is no associated increase in clusterin protein levels in AD 
CSF (Lidstrom et al., 2001) and the level of clusterin protein in CSF is decreased by 
2.5 fold in Creutzfeldt Jacob disease (Piubelli et al., 2006). In addition, decreased 
levels of clusterin in the eye are thought to be responsible for deposition of Pseudo 
exfoliation (PEX) material in PEX syndrome (Zenkel et al., 2006) (again clusterin is 
found associated with PEX deposits).  
 
Another factor that could favour the development of amyloid pathology is a 
dysfunction in the expression or function of relevant cell surface receptors (see Fig. 
(3)). Under some conditions, ECs may stabilize toxic conformations of substrate 
proteins with exposed hydrophobicity (see section 4.2). If receptor-mediated 
clearance is inadequate, the persistence of such toxic complexes could manifest as 
neuronal damage. In vitro assays demonstrated that when neuronal cells were in 
mixed cultures with astrocytes and microglia (which express receptors capable of 
specifically binding to ECs, e.g. LDLR family members), by complexing with Aβ, 
both clusterin and α2M were neuroprotective.  However, when neuronal cells were 
cultured alone, complexes of clusterin or α2M with Aβ were neurotoxic, suggesting 
that complexes of EC and aggregating protein may be toxic in the absence of receptor 
mediated endocytosis pathways. Moreover, there are increased plasma concentrations 
of several LRP ligands in AD patients, including ApoE, α1 anti-chymotrypsin and 
urokinase (Aoyagi et al., 1992; Licastro et al., 1995; Taddei et al., 1997) suggesting 
that LRP may be either overwhelmed, downregulated or faulty in AD. More recently, 
this has been confirmed by data showing that LRP expression at the BBB is decreased 
in AD patients and mouse models (Deane et al., 2004). As discussed above (section 
4.3), this is consistent with the results from mouse models where antibody-mediated 
blockade of megalin and LRP significantly prolonged the time taken to clear Aβ from 
the brain (Shibata et al., 2000; Bell et al., 2007).  
 
5.0 CONCLUSION & FUTURE DIRECTIONS 
 
In recent years there has been considerable progress in our understanding of protein 
deposition disorders. In particular our understanding of the nature and significance of 
amyloid formation and deposition and the role that these play in disease has taken 
dramatic leaps forward. Further advances in understanding of the mechanisms which 
control extracellular protein folding are likely to identify new strategies for effective 
disease therapies. This chapter focused on what little is known about quality control 
of the folding of amyloid forming proteins in the extracellular space of the brain. 
Since the EC field is still in its infancy, this chapter is necessarily speculative in a 
number of areas. However, it is quite clear that amyloid forming proteins such as Aβ 
and prion proteins are ‘chaperoned’ in the brain by what have become termed 
extracellular chaperones. It is proposed that once bound to misfolded proteins, 
extracellular chaperones guide them to specific receptors that function to direct 
proteins into lysosomes for degradation. In this scenario, specific receptors such as 
LRP and megalin are an integral and critical part of a quality control system which 
provides protection against dangerously hydrophobic proteins/peptides in the brain. 
Since relatively little is known about ECs and their role in protein deposition diseases 
many future directions are possible. Initially, it will be important to better understand 
the mechanism by which, under some conditions, ECs promote amyloid formation, as 
this has clear relevance to the development of any EC-based therapies. Certainly, it 
will be critical to evaluate the roles of ECs in a variety of in vivo models of protein 
deposition diseases. It may be possible to accelerate the pace of advances by utilizing 
innovative new disease models such as those developed using the fruit fly Drosophila. 
The short generation times and ease of genetic manipulation in these models create 
opportunities not accessible with mammalian systems. Much remains to be discovered, 
ensuring that exciting times lie ahead. 
Table 1. Summary of protein deposition disorders in the CNS and the extracellular chaperones known to be associated with them. 
 
 Disease Aggregating protein/peptide Location EC associated with deposit 
Alzheimer’s disease Aβ peptide Extracellular Clus (Calero et al., 2000), α2M (Fabrizi et al., 2001), Hp (Powers et al., 1981), SAP (Perlmutter et al., 1995) 
Spongiform encephalopathies Prion Protein Extracellular Clus (Chiesa et al., 1996; Freixes et al., 2004), α2M (Adler and Kryukov 2007), SAP (Ishii et al., 1984) 
Parkinson’s disease α-synuclein Intracellular Clus (Sasaki et al., 2002), SAP (Kalaria and Grahovac 1990), α2M(Nicoletti et al., 2002) 
Dementia with lewy bodies α-synuclein Intracellular Clus (Sasaki et al., 2002), SAP (Kalaria and Grahovac 1990) 
Frontotemporal dementia with Parkinsonsism Tau Intracellular Unknown 
Amytrophic lateral sclerosis Superoxide dismutase 1 Intracellular Unknown 
Huntington’s disease Huntingtin with poly Q expansion Intracellular Unknown 
Spinocerebellar ataxia’s 
Ataxins with poly Q expansion 
 
TATA box-binding protein with poly Q expansion 
Intracellular 
 
Intracellular 
Unknown 
 
Unknown 
Spinal and bulbar muscular atrophy Androgen receptor with poly Q expansion Intracellular Unknown 
Hereditary dentatorubral-pallidoluysian atrophy Atrophin-1 with poly Q expansion Intracellular Unknown 
Familial British dementia ABri Extracellular Clus (Ghiso et al., 1995), SAP (Rostagno et al., 2007) 
Familial Danish Dementia ADan Extracellular Clus (Lashley et al., 2006), SAP (Rostagno et al., 2007) 
Familial amyloid polyneuropathy TTR Extracellular Unknown 
Age related macular degeneration Drusen components Extracellular Clus (Sakaguchi et al., 2002), SAP (Ambati et al., 2003) 
Gelatinous drop-like corneal dystrophy Keratoepithelin Extracellular Clus (Nishida et al., 1999), SAP (Stix et al., 2005) 
Lattice type I corneal dystrophy M1S1 Extracellular Clus (Nishida et al., 1999), SAP (Stix et al., 2005) 
Pseudoexfoliation (PEX) syndrome PEX components Extracellular Clus (Zenkel et al., 2006), SAP (Schlotzer-Schrehardt et al., 1992) 
Down’s syndrome Aβ Extracellular Clus (Kida et al., 1995), SAP (Kalaria and Grahovac 1990) 
 
Figure 1. A schematic representation of some of the fates that await polypeptide 
chains in vivo. Newly synthesized polypeptides fold into their biologically active, 
native conformation, often via the transient formation of one or more partially 
unfolded intermediates. Failure to do so may result in the polypeptide experiencing 
other fates, including degradation or irreversible aggregation to form either disordered 
(amorphous) aggregates or highly organized amyloid fibrils. The formation of 
amyloid fibrils occurs via a nucleation dependent mechanism in which soluble 
prefibrillar oligomers or nuclei are formed during the lag phase. These oligomeric 
species then act as templates to sequester other aggregation-prone intermediates, 
leading to rapid fibril growth (represented by the exponential elongation phase) and 
subsequently, to the formation of insoluble mature amyloid fibrils. The plateau phase 
represents the steady state when maximum fibril growth has been reached. Adapted 
from (Chiti and Dobson 2006). 
 
Figure 2. Possible consequences for proteins when extracellular quality control 
mechanisms fail. An extracellular quality control process has recently been proposed 
whereby extracellular chaperones (EC) facilitate the clearance of non-native protein 
structures via receptor-mediated endocytosis and intracellular, lysosomal degradation. 
The existence of such a quality control mechanism ensures that proteins do not persist 
beyond their intended lifespan in the extracellular space. Failure of this system, at any 
of its stages, may potentially result in the onset of disease caused by the accumulation 
and/or deposition of i) cytotoxic species generated through the amyloid assembly 
pathway, ii) aberrantly folded structures and aggregates such as insoluble complexes 
of ECs and fibrillar material, or iii) degradation-resistant complexes (as exemplified 
by Aβ1-42 amyloid fibrils). 
 
Figure 3. The biphasic effects of chaperones on amyloid fibril formation. Under 
certain conditions, proteins readily self-associate into highly structured amyloid fibrils. 
The kinetics of the amyloid assembly process is often depicted as a sigmoidal curve to 
reflect the three distinct phases (i.e. lag, elongation and plateau; see also Figure 1) that 
characterizes the fibril formation pathway. This kinetic profile can be detected in vitro 
using real-time spectroscopic techniques, such as those that monitor fibril formation 
by measuring the relative binding of amyloid-specific dyes such as Congo-red and 
Thioflavin T. Such techniques have, in the past, provided clues as to what effects 
chaperones have on fibril formation. Using various model substrate proteins, it was 
shown that complete inhibition of fibril formation can be achieved when clusterin and 
α2M are present at high (but usually still sub-stoichiometric) levels relative to the 
substrate protein. Yet, at low EC:substrate ratios, extensive amyloid or amyloid-like 
fibril formation is observed for some substrate proteins, suggesting that in these cases, 
ECs may be stabilizing an otherwise unstable conformation and promoting amyloid 
fibril formation  
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